Adefovir dipivoxil and thymosin α_1 treatment of chronic hepatitis B clinical observation

OBJECTIVE To investigate the effectiveness of treatment of chronic hepatitis B by adefovir dipivoxil and combined with the thymosin α1 in combination.METHODS Cases were devided randomly into adefovir dipivoxil group and the joint treatment group.As to the conbination dipivoxil group,to inject adefovir dipivoxil 10 mg·d-1,for 48 weeks;As to the joint treatment group,besides the adefovir dipivoxil group therapy,plus thymosin α1 1.6 mg,subcutaneous injection,twice a week,last out 48 weeks.To observe the two groups of patients with biochemical response rate,virus response rate,HBeAg negative rate.RESULTS Adefovir dipivoxil group: 24 weeks later,biochemical response rate was 56%,virus response rate was 44 percent,HBeAg negative rate was 13%;48 weeks later,biochemical response rate was 72%,virus response rate was 59%,HBeAg negative rate was 41 percent.The joint treatment group: 24 weeks later,biochemical response rate was 87%,virus response rate was 73%,HBeAg negative rate was 40%;48 weeks later,biochemical response rate was 93%,virus response rate was 87%,HBeAg negative rate was 70%.CONCLUSION The effectiveness of treatment of chronic hepatitis B by adefovir dipivoxil is remarkable,and the efficacy continues improving with the time;if used with thymosin α1 together,there will be a more significant effect.